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Abstract: In this article, we illustrate the application of difference in-gel electrophoresis 
for the proteomic analysis of dystrophic skeletal muscle. The mdx diaphragm was used  
as a tissue model of dystrophinopathy. Two-dimensional gel electrophoresis is a widely 
employed protein separation method in proteomic investigations. Although two-dimensional 
gels usually underestimate the cellular presence of very high molecular mass proteins, 
integral membrane proteins and low copy number proteins, this method is extremely 
powerful in the comprehensive analysis of contractile proteins, metabolic enzymes, 
structural proteins and molecular chaperones. This gives rise to two-dimensional gel 
electrophoretic separation as the method of choice for studying contractile tissues in health 
and disease. For comparative studies, fluorescence difference in-gel electrophoresis has 
been shown to provide an excellent biomarker discovery tool. Since aged diaphragm fibres 
from the mdx mouse model of Duchenne muscular dystrophy closely resemble the human 
pathology, we have carried out a mass spectrometry-based comparison of the naturally 
aged diaphragm versus the senescent dystrophic diaphragm. The proteomic comparison of 
wild type versus mdx diaphragm resulted in the identification of 84 altered protein species. 
Novel molecular insights into dystrophic changes suggest increased cellular stress, 
impaired calcium buffering, cytostructural alterations and disturbances of mitochondrial 
metabolism in dystrophin-deficient muscle tissue. 
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1. Introduction 
Skeletal muscle proteomics is concerned with the global analysis of protein populations from 
voluntary contractile tissues. Starting material may consist of crude extracts from total muscle 
preparations, protein constellations from defined muscle-associated cell types, isolated organelles, 
supramolecular protein complexes or the fibre secretome. The separation of muscle proteins is usually 
performed by gel electrophoresis and/or liquid chromatography and followed by the computer-assisted 
analysis of proteomic maps. In order to reproducibly generate peptide signatures of separated proteins, 
standardized digestion protocols are applied in muscle proteomics. Mass spectrometry is the method of 
choice for the rapid and reliable identification of individual protein species by their peptide fingerprint 
or amino acid sequence. Immunoblotting surveys, immunofluorescence microscopy, biochemical assays 
and functional testing are usually carried out to verify large-scale proteomic data. Comprehensive 
reviews have critically examined the impact of mass spectrometry-based proteomics in basic and 
applied myology [1?3]. In the long-term, proteomic biomarker discovery promises to be instrumental 
for the swift identification of novel indicators that may decisively increase our knowledge base of 
basic physiological and complex pathophysiological mechanisms, as well as improve a variety of 
diagnostic, prognostic and therapeutic approaches in the field of neuromuscular disorders [4]. 
Various forms of high-resolution two-dimensional gel electrophoresis are routinely used for 
separating complex protein mixtures [5?7]. In the case of muscle proteomics, gel electrophoresis is 
highly suitable for the high-throughput analysis of the most abundant muscle proteins, such as 
myosins, actins, troponins, tropomyosins, glycolytic enzymes, mitochondrial proteins, cytoskeletal 
proteins and molecular chaperones [8]. Although the exact number of proteins representing the skeletal 
muscle proteome is not known, the accessible portion of proteins probably make up the majority of the 
skeletal muscle proteome [9]. The actomyosin apparatus and its auxiliary sarcomeric elements 
constitute nearly half of all muscle proteins [10], the enzymes of glycolysis represent the 10 most 
abundant proteins of the diffusible fraction of the vertebrate muscle proteome [11], mitochondrial 
proteins account for approximately one fifth of the muscle protein complement [12] and chaperones 
are also relatively abundant in skeletal muscle tissues [13]. Thus, gel-based studies with urea-soluble 
proteins cover a considerable portion of the total skeletal muscle proteome and are therefore suitable 
for both protein cataloging exercises and comparative studies. However, certain classes of protein  
are clearly underrepresented in proteomic approaches that employ gel electrophoresis as its main 
protein separation method [8]. These types of muscle-associated proteins include especially integral 
membrane proteins, very high molecular mass proteins and low-abundance proteins. To overcome this 
technical problem, other than using sophisticated liquid chromatography approaches [14], alternative 
electrophoretic methods can be employed to supplement routine 2D-gel based investigations.  
This includes agarose 2D gel electrophoresis [15,16], Native-Blue gel electrophoresis [17,18],  
non-reducing/reducing diagonal 2D gel electrophoresis [19,20], off-gel electrophoresis [21,22] and  
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on-membrane digestion of proteins separated by large one-dimensional gradient gels [23,24]. In 
addition to studies involving 2D gels, normal and diseased skeletal muscle tissues have been 
extensively studied by 1D gel electrophoresis coupled to HPLC-ESI-MS/MS analysis and quantitative 
approaches such as the SILAC or ICAT method [9,11,12,25?27]. Combined outcomes from gel-based 
and gel-free separation methods and data generation from labeling versus label-free MS analyses often 
result in complementary findings that can give a more comprehensive overview than that achieved by 
just using a single proteomic approach. 
Over the last few years, fluorescence two-dimensional difference in-gel electrophoresis has proven 
to be an excellent biomarker discovery tool for comparative studies in neuromuscular biology [28]. 
Originally described by Minden and co-workers [29], this key proteomic method can be used with 
fluorescent 2-CyDye or 3-CyDye systems to differentially label proteins from dissimilar protein 
mixtures prior to gel electrophoresis [30?32], as diagrammatically shown in Figure 1. Using optimized 
2D software analysis tools [33,34], advanced DIGE analysis can highly accurately quantitate multiple 
protein samples on the same 2D gel, which greatly reduces the introduction of potential artifacts due to 
gel-to-gel variations [35,36]. For comparative muscle proteomics, routinely 50 ??? ???????? ?????????
from individual fractions are labeled with Cy2, Cy3 or Cy5 dyes. Pre-electrophoretically labeled 
proteins usually account for a representative proportion of key contractile, structural, metabolic and 
regulatory muscle proteins [37]. In general, selective labeling artifacts do not appear to play a major 
role in the case of soluble protein species, as suggested by the statistical analysis of the experimental 
variation of DIGE gels [38]. This usually eliminates the need for reverse DIGE labeling controls 
during routine proteomic studies. Here, we have used the 2D-DIGE technique to demonstrate its 
unparalleled capability as a comparative analytical tool for the characterization of animal disease models. 
Animal models of human diseases are widely used in the initial identification of novel biomolecules 
involved in tissue degeneration [39]. In the field of experimental muscle pathology, a large number of 
animal genocopies are available to study the basic mechanisms of major neuromuscular diseases [40]. 
Although these genetic disease models are often not perfect phenocopies of a highly complex human 
etiology, proteomic screening of pathobiochemical changes in their expression profiles can be helpful 
for the initial identification of new biomarker candidates [41]. In the case of Duchenne muscular 
dystrophy, a lethal x-linked disorder of childhood that is caused by primary abnormalities in the dmd 
gene coding for the membrane cytoskeletal protein dystrophin [42], a variety of spontaneous and 
engineered animal models are available for biomedical studies [43,44]. Mammalian animal 
phenocopies of dystrophinopathy are highly valuable tools for elucidating the molecular pathogenesis 
of x-linked muscular dystrophy and developing novel therapeutic strategies [45,46]. Various muscle 
specimens from the mdx mouse model and the grmd dog have been used in mass spectrometry-based 
proteomic studies [25?27,37,47,48] including the successful evaluation of experimental exon-skipping 
therapy with novel proteomic biomarkers [49]. 
Building on the findings from previous proteomic studies of genetic animal models of muscular 
dystrophy [50] and the fact that aged muscle fibres from the dystrophic mdx mouse closely resemble 
the human pathology of Duchenne muscular dystrophy [51?54], we carried out here an optimized 
proteomic analysis of normal versus mdx tissues using aged mice. Recent proteomic investigations 
from our laboratories have analyzed young mdx versus senescent mdx muscles and shown a variety of 
protein changes in the dystrophin-deficient mouse during aging [48,55,56]. Here, we have directly 
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compared dystrophic mdx diaphragm with age-matched normal muscle from senescent mice. In 
agreement with severe degeneration occurring in the mdx diaphragm, proteomics revealed considerable 
changes in a variety of proteins in dystrophic diaphragm tissue. Altered proteins are associated with 
the contractile apparatus, the extracellular matrix, the cellular stress response, metabolite transport and 
mitochondrial energy metabolism. 
Figure 1. Overview of the fluorescence difference in-gel electrophoresis method: Shown 
are the main approaches used in fluorescence gel-based proteomics, whereby 2-dye or 3-dye 
difference in-gel electrophoresis (DIGE) is most commonly applied for studying global 
changes in complex protein populations. In the case of muscular dystrophy research, 
normal and dystrophic specimens are differentially labeled with CyDyes prior to 
electrophoresis, then proteins separated based on the unique combination of their isoeletric 
point and molecular masses and finally image analysis used to evaluate differential 
expression pattern of fluorescently labeled proteins. 
 
2. Experimental Section 
2.1. Chemicals and Materials 
For the gel electrophoresis-based proteomic analysis of aged diaphragm muscle, Coomassie 
Brilliant Blue, CyDye DIGE Fluor minimal dyes Cy3 and Cy5, ampholytes, acetonitrile, cover  
fluid and immobilised pH gradient (IPG) drystrips pH 3?11 were purchased from Amersham 
Biosciences/GE Healthcare (Little Chalfont, Buckinghamshire, UK). Acrylamide stock solutions were 
obtained as ultrapure Protogel from National Diagnostics (Atlanta, GA, USA). Laemmli-type 
electrophoresis buffer, protein molecular weight ladders and the Bradford reagent for protein 
quantification were purchased from Biorad Laboratories (Hemel-Hempstead, Hertfordshire, UK). For 
protein digestion, sequencing grade-modified trypsin was obtained from Promega (Madison, WI, 
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USA). Formic acid and LC-MS Chromasolv water were from Fluka (Milwaukee, WI, USA) and spin 
filters were purchased from Fisher Scientific (Loughborough, UK). To verify key proteomic findings 
by immunoblotting, primary antibodies were obtained from Abcam, Cambridge, UK (ab111233 to the 
cardiovascular heat shock protein cvHSP; ab43176 to ATP synthase; ab6588 to collagen; ab28172 to 
prohibitin; and ab11427 to parvalbumin), Sigma Chemical Company, Dorset, UK (ab L-9393 to 
laminin), Santa Cruz Biotechnology, Santa Cruz, CA, USA (ab sc-33701 to ?-dystroglycan), Affinity 
Bioreagents, Golden, CO, USA (mAb VIIID12 to fast calsequestrin) and Enzo Stressgen, Victoria, BC, 
Canada (ab ADI-SPA-811 to heat shock protein Hsp70/72). All secondary antibodies used were 
obtained from Chemicon International (Temecula, CA, USA). Protease inhibitors were from Roche 
Diagnostics (Mannheim, Germany). Ultrapure lysine for quenching the DIGE labelling reaction and all 
general reagents were obtained from Sigma Chemical Company (Dorset, UK). 
2.2. Preparation of Diaphragm Extracts from Aged mdx Mice 
Since the diaphragm muscle of the aged mdx mouse is: (i) missing dystrophin isoform Dp427 due to 
a point mutation [57]; (ii) closely resembles the fibre pathology of Duchenne muscular dystrophy [58]; 
and (iii) exhibits an accelerated progression of muscle degeneration [51?54], we have here  
used 22-month old samples from mdx diaphragm versus wild type diaphragm to study global changes 
in dystrophinopathy. Skeletal muscle specimens were obtained from the bioresource unit of the 
University of Bonn [55]. Animals were kept under standard conditions and all procedures were 
performed in accordance with German guidelines on the use of animals for scientific experiments. 
Senescent mdx mice and age-matched non-dystrophic mice were sacrificed by cervical dislocation and 
post-mortem diaphragm tissues quickly removed, quick-frozen in liquid nitrogen and stored at ?80 °C 
prior to usage. For the gel electrophoresis-based proteomic analysis of the mdx diaphragm, total 
muscle protein extracts from 4 dystrophic and 4 non-dystrophic muscle specimens were individually 
pulverized by grinding tissue pieces in liquid nitrogen using a mortar and pestle. A volume of 1 mL of 
lysis buffer, consisting of 2% IPG buffer pH 3?10, 7 M urea, 2 M thiourea, 4% CHAPS and 2% 
dithiothreitol, was employed to solubilize proteins from 100 mg of ground muscle powder. 
Importantly, the lysis buffer was supplemented with a freshly prepared protease inhibitor cocktail [37] 
to prevent excess protein degradation. The suspensions were centrifuged for 15 min at 15,000 × g at  
4 °C, following gentle rocking for 60 min, and then the protein concentration determined [48]. 
2.3. Fluorescence Two-Dimensional Difference In-Gel Electrophoretic Analysis of the Diaphragm 
Muscle Proteome 
For the pre-electrophoretic labeling of urea-soluble diaphragm muscle proteins, 50 ??? ????????
aliquots from individual samples were fluorescently labelled with Cy3 DIGE Fluor dye [59]. The 
pooled internal standard was labelled with Cy5 DIGE Fluor dye. Individual samples were mixed with 
the appropriate amount of dye at pH 8.5, carefully vortexed and then incubated on ice for 30 min in the 
dark. The reaction was quenched by the addition of 10 mM lysine [60]. Following the incubation of the 
dye-protein mixture with lysine for 10 min on ice in the dark, fluoresecently labelled protein samples 
were immediately loaded onto IPG strips for electrophoretic separation in the first dimension. The gel 
electrophoretic separation of diaphragm proteins was performed with a total amount of 100 ???????????
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per analytical 2D-DIGE gel. Standardized two-dimensional gel electrophoresis was carried out with 
isoelectric focusing in the first dimension using 24 cm pH 3?11 strips in a IPGphor system from 
Amersham Biosciences/GE Healthcare (Little Chalfont, Buckinghamshire, UK) using the following 
running conditions: 4 h at 80 V, 2 h at 100 V, 1.5 h at 500 V, 1.5 h at 1,000 V, 1 h at 2,000 V, 1 h at 
4,000 V, 2 h at 6,000 V and a final 2.5 h step at 8,000 V. IPG strips were then equilibrated twice for  
20 min using 6 M urea, 30% glycerol, 2% SDS and 100 mM Tris-HCl, pH 8.8. The first incubation 
step was carried out in the presence of 100 mM dithiothreitol and the second incubation step using 
0.25 M iodoacetamide. Subsequently IPG strips were washed in SDS running buffer (125 mM Tris, 
0.96 M glycine, 0.1% (w/v) sodium dodecyl sulfate) and placed on top of 12.5% slab gels and proteins 
separated in the second dimension with the help of an Amersham EttanDalt-twelve system [59]. 
Analytical slab gels were run in parallel at 0.5 W/gel for 60 min and then 15 W/gel until the blue dye 
front had disappeared from the bottom of the gel. A Typhoon Trio variable mode imager was used to 
visualize electrophoretically separated and DIGE-labelled diaphragm proteins. Protein expression 
changes between mdx specimens and non-dystrophic specimens were analyzed using Progenesis 
SameSpots analysis software [61] (Non Linear Dynamics, Newcastle upon Tyne, UK). Individual gels 
were warped to a single master gel and the following parameters used during analysis: n = 4; p < 0.05; 
and a power value of >0.8. Diaphragm proteins with a significantly changed concentration in mdx 
versus normal specimens were picked for tryptic digestion from Coomassie Blue-stained preparative 
gels [59]. 
2.4. Mass Spectrometric Identification of Diaphragm Proteins 
The unequivocal identification of individual diaphragm proteins, which exhibited a changed 
abundance in the aged mdx model of Duchennne muscular dystrophy, was carried out with 
corresponding protein spots from Coomassie-stained pick gels. Spots were excised, washed, destained 
and then digested with a previously optimized in-gel tryptic digestion protocol [62] and resulting 
peptide populations evaluated by electrospray ionization LC-MS/MS analysis [63] using a Model 6340 
Ion Trap LC/MS apparatus from Agilent Technologies (Santa Clara, CA, USA). Drying of peptide 
mixtures was carried out by vacuum centrifugation and samples then resuspended in MS-grade 
distilled water and 0.1% (v/v) formic acid, spun down through spin filters and added to LC-MS vials 
for mass spectrometric identification. Separation of peptides was performed with a nanoflow Aligent 
1200 series system. Peptide mixtures were loaded into the enrichment at a capillary flow rate set to  
2 ?L/min with a mix of 0.1% (v/v) formic acid and 50% (v/v) acetonitrile and formic acid at a ratio of 
19:1. The voltage was set to 2,000 V. Database searches were carried out using Mascot MS/MS Ion 
search. Criterion for each search was set at (i) species Mus musculus; (ii) two missed cleavages by 
trypsin; (iii) variable modification: oxidation of methionine; (iv) fixed modification: carboxymethylation 
of cysteines and (v) mass tolerance of precursor ions ±2 Da and product ions ±1 Da.  
2.5. Bioinformatics Analysis of Protein Classes and Potential Protein Interactions 
For the determination of clustering of molecular functions and the identification of potential protein 
interactions of the mass spectrometrically identified proteins with a changed abundance in dystrophic 
mdx diaphragm muscle, standard bioinformatics software was used. Analyses were performed with the 
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PANTHER ([64]; version 8.1) comprehensive database of protein families for the cataloging of 
molecular functions [65] and the STRING ([66]; version 9.1) database of known and predicted protein 
interactions that include direct physical and indirect functional protein associations [67]. 
2.6. Immunoblot Analysis 
For the independent verification of key proteomic hits, the abundance of ??????????-dystroglycan, 
collagen, cvHsp, Hsp70, prohibitin, parvalbumin, calsequestrin and ATP synthase was evaluated by 
immunoblotting of mdx diaphragm samples versus normal muscle samples. One-dimensional gel 
electrophoresis and immunoblot analysis were carried out by a standard protocol, as previously 
described in detail [62]. The electrophoretic separation of diaphragm proteins from 22-month old mdx 
mice and age-matched normal mice was performed with 5%?10% gradient SDS-PAGE gels. 
Electrophoretic transfer was carried out at 100 V for 70 min using Whatman Protan nitrocellulose 
sheets and a Transblot Cell from BioRad Laboratories (Hemel Hempstead, Hertfordshire, UK). Blots 
were blocked for 1 hour with a 5% (w/v) fat-free milk protein solution in phosphate-buffered  
saline [68]. Following incubation with 1:1,000 diluted primary antibodies for 3 h with gentle agitation 
at 4 °C, membranes were washed 3 times for 10 min and then re-incubated for 1 h at 4 °C with secondary 
peroxidase-conjugated antibodies diluted in blocking solution. Finally, blots were washed again and 
the immuno-decorated protein bands visualized by the enhanced chemiluminescence method. 
Densitometric scanning and evaluation of immunoblots was performed with a HP PSC-2355 scanner 
and ImageJ (NIH, Bethesda, MD, USA) and GraphPad Prism (San Diego, CA, USA) software. 
3. Results 
3.1. Overview of Proteomic Surveys of the mdx Animal Model of Duchenne Muscular Dystrophy 
The optimization of animal models is a crucial part of biomedical proteomics and proteomic 
biomarker discovery. In the field of muscular dystrophy research, the mdx mouse is a widely used 
model system to study the molecular pathogenesis of dystrophinopathy and the suitability of novel 
experimental therapies to counteract dystrophic symptoms. We have recently reviewed the past usage 
of mass spectrometry-based proteomics to study the dystrophin-glycoprotein complex and secondary 
changes in the dystrophic mdx mouse [69]. Figure 2 summarizes the various age groups and types of 
muscle evaluated by proteomics and also gives an outline of the comparative proteomic approach used 
in this report. It is important to stress that the majority of muscles in the mdx mouse exhibit moderate 
symptoms, such as segmental necrosis in hind limb muscles. Certain mdx muscles, such as extraocular 
fibres or the interosseus muscle are even less necrotic than tibialis anterior, extensor digitorum longus, 
gastrocnemius or soleus muscles. In contrast, the mdx diaphragm muscle is severely affected by the 
deficiency in the membrane cytoskeletal protein dystrophin [58], and aging was shown to exacerbate 
the dystrophic phenotype [55]. Thus, the senescent mdx diaphragm muscle most closely resembles the 
human pathology. We therefore optimized here the usage of the mdx mouse for animal model 
proteomics. Using fluorescence difference in-gel electrophoresis, we have created a proteomic reference 
map of the senescent mdx diaphragm. This represents a highly improved proteomic application within 
the field of muscular dystrophy research. 
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Figure 2. Mass spectrometry-based proteomic profiling of the mdx mouse model of 
Duchenne muscular dystrophy: The upper panel of the figure summarizes the types of 
muscle and age groups of mdx mice that have been used over the last few years to  
identify global changes in the dystrophic muscle proteome. All listed proteomic studies 
have been recently discussed in comprehensive reviews of the proteomics of the 
dystrophin-glycoprotein complex and dystrophinopathy [50,69]. The lower panel gives  
an overview of the difference in-gel electrophoretic (DIGE) analysis of the aged mdx 
diaphragm muscle presented in this report. 
 
3.2. Fluorescence Two-Dimensional Difference In-Gel Electrophoretic Analysis of the Naturally Aged 
versus the Aged mdx Diaphragm Muscle 
In order to determine the extent of secondary changes in the senescent mdx diaphragm proteome 
due to deficiency in the membrane cytoskeletal protein dystrophin, the urea-soluble protein repertoire 
from 22-month old wild type versus age-matched dystrophic diaphragm muscle was investigated. 
Following fluorescent tagging with the CyDye Cy3 of wild type or mdx samples, as well as  
fluor labeling of the pooled standard using the CyDye Cy5, a detailed densitometric analysis of  
two-dimensional gels was performed with a Typhoon Trio variable imager and Progenesis 2D analysis 
software. Figure 3 gives an overview of this standard image analysis approach used in skeletal muscle 
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proteomics and highlights the opposite changes in the expression of the cytosolic Ca2+-binding protein 
parvalbumin versus the small heat shock protein HspB7/cvHsp in the dystrophic diaphragm. The 
proteomic comparison of wild type versus mdx diaphragm muscle identified 84 altered protein species 
in 22-month old muscle extracts. A 2D-DIGE master gel of the mdx diaphragm muscle is shown in 
Figure 4. The 2D protein spots with a significant change in abundance are marked by circles and their 
numbering from 1 to 84 corresponds to the list of identified proteins in Table 1. 
Figure 3. Image analysis of fluorescent DIGE gels representing normal versus dystrophic 
diaphragm muscle: Shown are a 2D-DIGE master gel used for the analysis of aged mdx 
diaphragm (A), the visualization of the altered expression levels of the cytosolic  
Ca2+-binding protein parvalbumin (PVA; B, D, E) and the small molecular chaperone 
cvHsp (C, F, G), the variability of detected alterations between normal and dystrophic 
samples (H, I) and the graphical presentation of the drastic decrease in parvalbumin (J, K) 
and the up-regulation of cvHsp (L, M) in dystrophic muscle. In this study, a Typhoon Trio 
variable mode imager was employed for the visualization of electrophoretically separated 
and CyDye-labelled diaphragm proteins. Expression changes of proteins between wild type 
samples and dystrophic mdx samples were determined with the help of Progenesis 
SameSpots analysis software. 
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Figure 4. 2D-DIGE master gel of the aged mdx diaphragm muscle: Shown is a 2D master 
gel that is representative of the findings of the fluorescence two-dimensional difference  
in-gel electrophoretic analysis of the aged mdx diaphragm. Protein spots with a significant 
change in expression levels between normal and dystrophic specimens are marked by 
circles and are numbered 1 to 84. See Table 1 for the mass spectrometric identification of 
individual diaphragm-associated proteins. The pH-values of the first dimension gel system 
and molecular mass standards of the second dimension are indicated on the top and on the 
left of the panels, respectively. 
 
3.3. Mass Spectrometric Identification of Altered Proteins in Aged mdx Diaphragm Muscle 
The mass spectrometric identification of the 27 increased and 57 decreased protein species in the 
dystrophin-deficient and aged diaphragm is listed in Table 1, as well as their accession number, 
MS/MS score, isoelectric point, molecular mass, number of peptides, percent sequence coverage and 
fold change. Identified proteins ranged in molecular mass from 11.9 kDa (Parvalbumin) to 87.7 
(Nebulin fragment), and isoelectric points ranged from pI 4.07 (Troponin C) to pI 9.19 (Nebulin 
fragment). Most of the identified muscle-associated proteins belong to the contractile apparatus, the 
cellular stress response, the extracellular matrix, ion homeostasis and energy metabolism. An increased 
concentration was shown for dermatopontin (spots 1 to 3), the small heat shock protein HspB7/cvHsp 
(spot 4), myosin light chain 6B (spot 5), unnamed protein products (spots 7, 17 and 26), beta-actin 
(spot 10), heat shock protein Hsp70 cognate (spots 11, 21 and 22), mitochondrial stress-70 protein 
(spots 12 and 24), smooth muscle gamma-actin (spot 13), a fragment of nebulin (spot 14), lumican 
(spot 15), prohibitin (spot 16), transferrin (spot 18), annexin A5 (spot 19), heat shock protein 8  
(spot 23), Fmod protein (spot 25) and 78 kDa glucose-regulated protein (spot 27). 
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Table 1. List of identified proteins that exhibit a drastic change in abundance in the aged 
mdx diaphragm as revealed by 2D-DIGE analyses. 










1 Dermatopontin NP_062733 73 4.7 24,559 5 28 5.9 
2 Dermatopontin NP_062733 111 4.7 24,559 7 37 4.4 
3 Dermatopontin NP_062733 100 4.7 24,559 6 26 3.4 
4 Heat shock protein HspB7 (beta7, cvHsp) NP_038896 87 5.95 18,681 5 38 3.3 
5 Myosin light chain 6B  NP_758463 181 5.41 22,851 14 74 3.1 
6 Tropomyosin, beta chain isoform 1 NP_033442 319 4.66 32,933 22 61 2.9 
7 Unnamed protein product BAE35818 286 5.78 70,776 15 30 2.8 
8 Myosin light chain 1/3, isoform 1f, muscle NP_067260 97 4.98 20,697 2 12 2.7 
9 Tropomyosin, beta chain isoform 1 NP_033442 107 4.66 32,933 11 35 2.7 
10 Actin, beta (aa 27?375) CAA27396 124 5.78 39,451 9 21 2.6 
11 Heat shock protein Hsp70 cognate AAA37869 110 5.37 71,025 11 23 2.6 
12 Mitochondrial stress-70 protein  BAA04493 57 5.91 73,773 1 1 2.6 
13 Actin, gamma, smooth muscle  AAC52237 81 5.36 43,258 5 16 2.6 
14 Nebulin (fragment) AAF59979 53 9.19 87,694 4 7 2.5 
15 Lumican  AAB35361 103 5.84 38,733 2 5 2.4 
16 Prohibitin  NP_032857 350 5.57 29,860 15 69 2.4 
17 Unnamed protein product BAC34145 129 5.75 70,766 8 14 2.4 
18 Transferrin AAL34533 168 6.92 78,832 19 24 2.3 
19 Annexin A5 NP_033803 249 4.83 35,788 16 45 2.3 
20 Alpha-fetoprotein AAA37190 112 5.47 48,819 2 6 2.2 
21 Heat shock protein Hsp70 cognate  AAA37869 110 5.37 71,025 11 23 2.2 
22 Heat shock protein Hsp70 cognate  AAA37869 77 5.37 71,025 4 6 2.2 
23 Heat shock protein 8 AAH66191 110 5.28 71,060 11 23 2.2 
24 Mitochondrial stress-70 protein  BAA04493 71 5.91 73,773 5 9 2.1 
25 Fmod protein AAH52673 92 5.56 46,637 2 4 2.1 
26 Unnamed protein product  BAC34145 254 5.75 70,766 8 17 2.1 
27 78 kDa glucose-regulated protein  BAA11462 112 5.09 72,528 7 15 2.0 
28 Myosin light chain 1/3, isoform 1f, muscle NP_067260 222 4.98 20,697 15 63 ?2.0 
29 Parvalbumin, alpha  NP_038673 156 5.02 11,923 6 57 ?2.0 
30 Malate dehydrogenase  AAA39509 90 8.93 36,052 3 11 ?2.1 
31 ATP synthase, beta-subunit AAB86421 98 5.14 56,344 2 4 ?2.1 
32 Tropomyosin, beta chain gi|11875203 180 4.66 32,933 11 32 ?2.1 
33 Alpha-fetoprotein AAA37190 95 5.47 48,819 2 5 ?2.1 
34 Isocitrate dehydrogenase subunit alpha NP_083849 242 6.27 40,077 6 20 ?2.1 
35 L-lactate dehydrogenase B chain  NP_032518 54 5.7 36,839 5 12 ?2.1 
36 Actin, alpha, cardiac gi|387090 51 5.23 42,048 2 7 ?2.1 
37 
Coiled-coil-helix-coiled-coil-helix  
domain-containing protein 3, mitochondrial 
NP_079612 80 8.56 26,550 5 24 ?2.1 
38 Cu/Zn superoxide dismutase 1513495A 147 6.03 15,926 5 41 ?2.1 
39 Malate dehydrogenase mitochondrial  NP_032643 256 8.93 36,053 12 45 ?2.1 
40 Peroxiredoxin Prdx1 NP_035164 97 8.26 22,394 11 47 ?2.1 
41 Malate dehydrogenase mitochondrial NP_032643 343 8.93 36,053 15 56 ?2.1 
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Table 1. Cont. 










42 Cytochrome c oxidase, subunit Va CAA34085 125 6.08 16,252 8 48 ?2.2 
43 ATP synthase, mitochondrial F0 complex AAH16547 148 5.52 18,810 5 47 ?2.2 
44 Heat shock protein Hsp beta-6 NP_001012401 130 5.64 17,568 6 51 ?2.2 
45 Creatine kinase, M-type NP_031736 276 6.58 43,250 9 27 ?2.2 
46 Malate dehydrogenasemitochondrial NP_032643 243 8.93 36,053 9 36 ?2.2 
47 Troponin C, skeletal muscle NP_033420 238 4.07 18,156 3 28 ?2.2 
48 Troponin C, skeletal muscle NP_033420 774 4.07 18,156 8 53 ?2.3 
49 Malate dehydrogenase 2, mitochondrial ABD77283 365 7.7 32,121 7 28 ?2.3 
50 Myoglobin NP_038621 61 7.07 17,117 1 9 ?2.3 
51 Myosin light chain 1/3, isoform 1f, muscle NP_067260 93 4.98 20,697 4 17 ?2.3 
52 Creatine kinase, M-type NP_031736 297 6.58 43,250 10 28 ?2.3 
53 Fatty acid-binding protein FABP3 NP_034304 157 6.11 14,810 6 48 ?2.3 
54 Calcium-binding protein NCS-1-like XP_003945963 48 6.49 12,957 1 17 ?2.4 
55 Electron transferring flavoprotein,alpha AAH03432 449 8.62 35,366 11 44 ?2.4 
56 Isocitrate dehydrogenase subunit alpha NP_083849 167 6.27 40,077 6 19 ?2.4 
57 Malate dehydrogenase 2, mitochondrial ABD77283 85 7.7 32,121 2 8 ?2.4 
58 Creatine kinase, M-type NP_031736 404 6.58 43,250 11 33 ?2.4 
59 ATP synthase, subunit d, mitochondrial NP_082138 168 5.52 18,796 11 70 ?2.4 
60 Electron transfer flavoprotein, subunit alpha NP_663590 195 8.62 35,336 8 39 ?2.5 
61 Cofilin-2 NP_031714 158 7.66 18,814 5 36 ?2.5 
62 Adenylate kinase, isoenzyme AK1 NP_067490 104 5.7 23,334 6 36 ?2.5 
63 ATP synthase, beta-subunit AAB86421 301 5.14 56,344 6 16 ?2.6 
64 Tropomyosin, beta chain gi|11875203 129 4.66 32,920 10 25 ?2.6 
65 Myosin light chain MLC2, skeletal muscle NP_058034 93 4.82 19,059 2 8 ?2.7 
66 Fumarate hydratase 1 AAH06048 173 9.12 54,568 6 17 ?2.8 
67 Myosin light chain 1/3, isoform 1f, muscle NP_067260 201 4.98 20,697 11 53 ?2.9 
68 Ubiquinone biosynthesis protein COQ9 NP_080728 150 5.6 35,235 5 21 ?3.0 
69 Calsequestrin, skeletal muscle AAC63616 143 3.93 45,619 8 22 ?3.1 
70 Creatine kinase, M-type NP_031736 505 6.58 43,250 10 31 ?3.1 
71 Myoglobin NP_038621 124 7.07 17,117 6 48 ?3.1 
72 Myoglobin NP_038621 59 7.07 17,117 1 11 ?3.2 
73 Myosin light chain MLC2, skeletal muscle NP_058034 267 4.82 19,059 15 68 ?3.4 
74 Creatine kinase, M-type NP_031736 266 6.58 43,250 11 31 ?3.5 
75 Myosin light chain 1/3, isoform 1f, muscle NP_067260 87 4.98 20,697 2 12 ?3.6 
76 Myoglobin NP_038621 91 7.07 17,117 2 21 ?3.7 
77 Malate dehydrogenase  AAA39509 126 8.93 36,052 5 20 ?3.7 
78 Fatty acid-binding protein FABP3 NP_034304 426 6.11 14,810 11 77 ?3.7 
79 Myoglobin NP_038621 129 7.07 17,117 6 46 ?4.0 
80 Parvalbumin, alpha  NP_038673 285 5.02 11,923 6 57 ?4.0 
81 Myoglobin NP_038621 89 7.07 17,117 6 41 ?4.3 
82 Fatty acid-binding protein FABP3 NP_034304 188 6.11 14,810 7 63 ?5.3 
83 Fatty acid-binding protein FABP3 NP_034304 532 6.11 14,810 9 71 ?5.3 
84 Parvalbumin alpha  NP_038673 431 5.02 11,923 8 57 ?10.5 
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In contrast, a decreased concentration was established for parvalbumin (spots 29, 80 and 84), 
various isoforms of malate dehydrogenase (spots 30, 39, 41, 46, 49, 57 and 77), ATP synthase  
(spots 31, 43, 59 and 63), isocitrate dehydrogenase (spot 35), actin (spot 36), mitochondrial  
coiled-coil-helix-coiled-coil-helix domain-containing protein 3 (spot 37), Cu/Zn superoxide dismutase 
(spot 38), peroxiredoxin (spot 40), cytochrome c oxidase (spot 42), heat shock protein Hsp beta-6  
(spot 44), creatine kinase (spots 45, 52 and 74), troponin C (spots 47 and 48), myoglobin (spots 50, 71, 
72, 76, 79 and 81), fatty acid-binding protein FABP3 (spots 53, 78, 82 and 83), calcium-binding 
protein NCS-1 (spot 54), electron transferring flavoprotein (spots 55 and 60), isocitrate dehydrogenase 
(spot 56), cofilin (spot 61), adenylate kinase AK1 (spot 62), myosin light chain MLC2 (spots 65 and 
73), fumarate hydratase (spot 66), ubiquinone biosynthesis protein COQ9 (spot 68) and calsequestrin 
(spot 69). 
Proteins with differential expression patterns were identified as myosin light chain 1/3,  
alpha-fetoprotein and the beta chain of tropomyosin. Individual 2D protein spots representing the 
muscle isoform 1f of myosin light chain 1/3 were shown to be both increased (spot 8) and decreased 
(spots 28, 51, 67 and 75). In the case of the beta chain of tropomyosin, both increased (spots 6 and 9) 
and decreased (spots 32 and 64) concentrations of individual isoforms were determined. The  
alpha-fetoprotein exhibited increased (spot 20), and decreased (spot 33) levels. Although spots 12, 50, 
54 and 72 were only recognized by 1 peptide, they were included in Table 1 based on their MS/MS 
scores of 57, 61, 48 and 59, respectively. All other proteins were identified by at least 2 peptides. 2D 
protein spots with a molecular mass and/or isoelectric point that differ substantially from the 
biochemical properties of its identified protein are probably due to streaking effects based on  
cross-contamination with abundant proteins, extensive post-translational modifications, proteolytic 
fragmentation or non-specific protein clustering. 
3.4. Changed Protein Classes and Predicted Interaction Patterns of Altered Proteins  
Figure 5 provides an overview of the distinct classes of proteins, which have been identified by 
proteomics to be altered in mdx diaphragm muscle. The application of the PANTHER database of 
protein families [64,65] resulted in the cataloging of molecular functions of the identified muscle 
proteins as being involved in ion homeostasis, the cellular stress response, cytoskeletal stabilization, 
extracellular matrix organization, structural integrity, metabolic transportation and metabolism. Large 
groups of proteins were represented by calcium-binding proteins, cytoskeletal proteins and 
oxidoreductases. Frequent changes were also observed in molecular chaperones, kinases, structural 
proteins, transferases and carrier proteins. Relatively few alterations were shown to occur in 
extracellular matrix proteins. 
The STRING database of direct physical and indirect functional protein interactions [66,67] was 
employed to evaluate potential protein networks within the proteomic data set generated by this study 
of the aged mdx diaphragm. This bioinformatic analysis revealed a relatively complex interaction map 
(Figure 6). Two large clusters were shown to exist that are linked via adenylate kinase and creatine 
kinase interactions. Since both proteins were demonstrated to be reduced in dystrophin-deficient fibres, 
this indicates that more severe downstream effects on various proteins may occur within these apparent 
protein clusters. One of the identified protein networks consists especially of enzymes involved in 
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mitochondrial metabolism, such as ATP synthase, isocitrate dehydrogenase, aconitase and malate 
dehydrogenase. Another protein cluster contains several major contractile elements, including 
tropomyosin, troponin and myosins. Important ion handling proteins and metabolite transporters are 
also proposed to interact with these protein complexes. 
3.5. Immunoblot Analysis of Altered Proteins in Aged mdx Diaphragm Muscle 
In order to independently verify the status of potential biomarker candidates with a drastically 
altered expression in aged mdx diaphragm as revealed by proteomics, comparative immunoblotting 
was employed. Figure 7A shows a silver-stained 1D gel of non-dystrophic wild type versus dystrophic 
mdx diaphragm preparations. The gel exhibits relatively comparable overall protein banding patterns in 
both types of muscle. Immunoblotting of laminin revealed no significant difference in expression 
levels of this component of the basal lamina (Figure 7B). To confirm the mutant status of the mdx 
diaphragm specimens used in this study, the concentration of ?-dystroglycan was evaluated. 
Immunoblotting clearly showed a drastic reduction in this dystrophin-associated glycoprotein  
(Figure 7C). In contrast, the extracellular matrix protein collagen was found to be significantly 
increased in its expression, which agrees with the senescent and dystrophic status of the aged mdx 
diaphragm muscle. 
Figure 5. Molecular function of altered mdx diaphragm-associated proteins: The 
bioinformatics software programme PANTHER (database; version 8.1; [64,65]) was  
applied to identify the clustering of molecular functions of the mass spectrometrically 
identified proteins with a changed abundance in aged mdx diaphragm as compared to 
normal muscle (Table 1).  
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Figure 6. Interaction map of altered mdx diaphragm-associated proteins: The bioinformatics 
STRING database (version 9.1; [66,67]) was used to generate a protein interaction map 
with known and predicted protein associations that include direct physical and indirect 
functional protein linkages of the mass spectrometrically identified proteins with a changed 
abundance in aged mdx diaphragm as compared to normal muscle (Table 1). 
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Figure 7. Gel electrophoretic and immunoblot analysis of the aged mdx diaphragm muscle: 
Shown is a silver-stained gel (A) and representative immunoblots (B?D) with expanded 
views of antibody-decorated bands. Lanes 1 and 2 represent preparations from  
non-dystrophic wild type (WT) versus dystrophic (MDX) diaphragm muscle, respectively. 
Immuno-decoration was carried out with primary antibodies to laminin (B), the  
dystrophin-associated glycoprotein ?-dystroglycan (C) and collagen (D). Below the 
individual immunoblots are shown panels, which give a graphical representation of the 
immuno-decoration levels in normal versus mdx ????????????? ??????????? t-test, unpaired;  
n = 4; * p < 0.05; ** p < 0.01). 
 
Figure 8 shows immunoblot labeling that clearly verified the increase of 3 distinct diaphragm 
proteins and the concomitant decrease of 3 other diaphragm proteins. An increased concentration in 
dystrophic muscle was shown for the small heat shock protein cvHsp, the molecular chaperone Hsp70 
and the mitochondrial protein prohibitin (Figure 8A?C). In contrast, the cytosolic Ca2+-binding protein 
parvalbumin, the luminal Ca2+-binding protein calsequestrin and the mitochondrial enzyme ATP 
synthase were confirmed to be decreased in senescent mdx diaphragm (Figure 8D?F). The immunoblot 
analysis of calsequestrin with monoclonal antibody VIIID12 to the fast CSQ isoform showed besides 
the major 60 kDa band of its monomer also several high molecular mass bands that represent 
previously characterized calsequestrin-like proteins [70]. 
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Figure 8. Immunoblot analysis of the aged mdx diaphragm muscle: Shown are representative 
immunoblots with expanded views of antibody-decorated bands. Lanes 1 and 2 represent 
preparations from non-dystrophic wild type (WT) versus dystrophic (MDX) diaphragm 
muscle, respectively. Immuno-decoration was carried out with primary antibodies to heat 
shock protein cvHsp (A), heat shock protein Hsp70 (B), prohibitin (C), parvalbumin (D), 
the luminal Ca2+-binding protein calsequestrin (E) and the mitochondrial enzyme ATP 
synthase (F). Besides the individual immunoblots are shown panels, which give a graphical 
representation of the immuno-decoration levels in normal versus mdx preparations 
(??????????t-test, unpaired; n = 4; * p < 0.05; ** p < 0.01, *** p < 0.001). 
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4. Discussion and Conclusions 
The comprehensive cataloguing of tissue-specific mRNA profiles, protein populations and metabolite 
fluxes in normal biosystems is now a major undertaking in the modern biosciences following the 
successful determination of key mammalian genomes. In addition to the establishment of biomolecular 
constellations under normal physiological conditions, the high-throughput screening of disease-related 
alterations in the genome, transcriptome, peptidome, proteome and metabolome promises the 
systematic identification of novel biomarkers of pathophysiological adaptations and degenerative 
pathways. Importantly, the differential large-scale analysis of the full complement of genes, mRNAs, 
peptides, proteins and metabolites present in a defined biological entity, such as body fluids, 
subcellular fractions, cells, tissues or organisms, is an unbiased technology-driven approach [71?73]. 
Thus, key protein biochemical techniques such as mass spectrometry-based proteomics represent a 
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hypothesis-generating method in discovery mode that aims at the swift establishment of biomarker 
signatures. In contrast to conventional hypothesis-driven bioresearch that routinely focuses on a select 
number of protein factors, disease proteomics attempts to evaluate global changes in the entire protein 
collection of a cellular system [74]. Besides using secreted or leaked proteins as a rich source for 
biomarker discovery [75], changes in the abundance, oligomerisation, interactions and/or  
post-translational modifications in tissue-associated proteins are an excellent basis for establishing 
novel candidate markers [76]. 
Since single gene disorders that result from a distinct genetic rearrangement or mutations in a 
unique gene, such as Duchenne muscular dystrophy, have a defined primary genetic marker, these 
inherited diseases usually exhibit a corresponding and diagnostically accessible faulty protein as an 
expression marker [42]. This makes this particular type of genetic disorders relatively easy to evaluate 
on the molecular genetic level, as compared to many complex disorders with potential interplays 
between genetic susceptibility, life style and environmental factors. However, single gene disorders of 
the neuromuscular system often show highly complex secondary alterations in their proteome, making 
it difficult to understand potential hierarchies in degenerative pathways and thus hamper the 
development of reliable stage-specific diagnostic or prognostic procedures. In this respect, muscle 
proteomics suggests itself as a highly appropriate screening technique for identifying novel indicators 
of disease progression [4]. The comparative analysis of the naturally aged diaphragm versus the 
dystrophic mdx diaphragm presented here illustrates that the fluorescence difference in-gel 
electrophoresis method, in combination with optimized animal model proteomics, can be extremely 
helpful for the establishment of new protein markers involved in the molecular pathogenesis of 
dystrophinopathy. Biomarker discovery studies with rodent models are relatively cost-effective and 
aging studies can be carried out in a convenient period of time. In addition, more complex animal 
models of muscular dystrophy have been employed in the search for new markers of dystrophinopathy. 
This includes the grmd dog model of Duchenne muscular dystrophy [25]. 
The diagrammatic presentation in Figure 9 summarizes the proteomic findings from the analysis of 
the senescent mdx mouse model of Duchenne muscular dystrophy. Global alterations in contractile 
proteins, structural proteins, extracellular proteins, calcium-binding proteins, molecular chaperones, 
mitochondrial enzymes, glycolytic enzymes and metabolite transporters indicate rearrangements 
within the actomyosin apparatus, changes in the cytoskeletal network and its indirect linkage to the 
extracellular matrix, impaired ion handling, an enhanced cellular stress response and considerable 
metabolic disturbances. Overall, these results imply that protein expression patterns are drastically 
perturbed in the Dp427-deficient mdx diaphragm and that these pathobiochemical changes are more 
intense as compared to mdx hind limb muscle [26,47,56]. High levels of dermatopontin and a 
concomitant increase in collagen, as previously shown by proteomics [55], agree with a progressive 
accumulation of connective tissue in the dystrophic diaphragm [77]. The degeneration and/or  
re-modeling of the contractile apparatus, as shown here to include troponins, tropomyosin, actin and 
myosin light chains, and elevated levels of fibrosis appear to be accompanied by drastic changes in 
various heat shock proteins. This includes the up-regulation of the muscle-specific molecular 
chaperone cvHsp and several isoforms of Hsp70, which agrees with the general idea of severe cellular 
stress in dystrophinopathy [37]. Interestingly, increased levels of a nebulin fragment were observed 
indicating a potential compensatory mechanism to stabilize the weakened sarcomeric structure by 
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strengthening the nebulin-associated thin filament in dystrophic fibres [10]. The 2-fold increase in 
transferrin could be due to changes in iron absorption and usage in muscular dystrophy. Since 
circulating transferrin delivers essential iron to tissue proteins [78], the elevated concentration of this 
iron transporter indicates disturbed iron homeostasis in degenerating mdx diaphragm muscle. 
Figure 9. Proteomic profile of the aged mdx diaphragm muscle: The diagram summarizes 
the main classes of diaphragm proteins identified by the proteomic profiling of the aged 
and dystrophin-deficient mdx mouse model of X-linked muscular dystrophy. The severely 
perturbed protein expression pattern of dystrophic muscle tissue includes extracellular 
matrix proteins, contractile proteins, structural proteins, molecular chaperones, mitochondrial 
enzymes, glycolytic enzymes, calcium-binding proteins and metabolite transporters. Thus, the 
deficiency in dystrophin isoform Dp427 and concomitant reduction in dystrophin-associated 
glycoproteins in the dystrophic sarcolemma appears to trigger a large range of secondary 
abnormalities in muscular dystrophy. 
 
Previous studies have shown that skeletal muscles from the mdx mouse exhibit impaired 
mitochondrial metabolism resulting in decreased intramuscular ATP levels. Mitochondrial 
abnormalities include the pathophysiological uncoupling of oxidative phosphorylation and a 
concomitant reduced capacity for maximal ATP synthesis [79] and a disruption of the subsarcolemmal 
localization of mitochondria that promotes metabolic inefficiency and thus restricts the maximal 
generation of ATP [80]. In analogy to the findings from a recent proteomic study of the aged mdx  
heart [48], the senescent mdx diaphragm seems to also show a bioenergetic dysfunction of 
mitochondria and this suggests that aged mitochondria are unable to meet ATP demand in dystrophic 
muscle fibres. A decreased concentration was observed for key mitochondrial enzymes, including 
isocitrate dehydrogenase, malate dehydrogenase, cytochrome c oxidase, electron transferring 
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flavoprotein and ATP synthase. In addition, the proteomic findings of a reduced concentration of the 
essential and rate-limiting metabolite transporters for the utilization of fatty acids and oxygen, fatty 
acid binging protein FABP3 and the intracellular oxygen transporter myoglobin, agree with the 
concept of impaired oxidative metabolism. 
Over the last few years, comparative studies with mdx muscle tissue extracts have indicated 
significant changes in the enzyme adenylate kinase AK1 [37,47,81], the Ca2+-binding protein 
calsequestrin and its high-molecular-mass isoforms [68,82], the cytosolic Ca2+-binding protein 
parvalbumin [83], the actin binding protein profilin [26], the oxygen carrier myoglobin [81], the 
molecular chaperone cvHsp/HspB7 [37,49], different isoforms of annexin [26], the lysosomal-associated 
membrane protein LAMP1 [27], the enzyme carbonic anhydrase CA3 [56], the fatty acid binding 
protein FABP3 [26], the mitochondrial enzyme isocitrate dehydrogenase [26,83,84], the extracellular 
matrix protein dermatopontin [55] and the ion transporter transferrin [48,85]. These proteomic 
screening studies of the mdx mouse were carried out with a great variety of subtypes of muscle, 
various tissue extracts or subcellular fractions, diverse protein separation approaches, differing labeling 
methods and numerous mass spectrometric techniques [26,27,37,47?49,55,56,81?85]. 
The proteomic analysis presented here has confirmed that the concentration of cvHsp, 
dermatopontin, annexin, profilin and transferrin is drastically increased and that the abundance of 
calsequestrin, parvalbumin, myoglobin, isocitrate dehydrogenase, and adenylate kinase is severely 
reduced in the aged mdx diaphragm model of Duchenne muscular dystrophy. This makes these 
proteins excellent biomarker candidates of dystrophinopathy, which might be helpful in improving 
diagnostic, prognostic or therapeutic approaches. In conclusion, the proteomic analysis shown here 
establishes the suitability of the fluorescence difference in-gel electrophoresis method for studying 
highly complex contractile tissues in a comparative fashion and demonstrates that the aged mdx 
diaphragm represents a suitable model system to study secondary effects of dystrophin deficiency in 
skeletal muscle tissue.  
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